Cleveland Clinic Foundation and Health System appointed Michael O'Boyle chief operating officer.
Harvard Medical School-Partners HealthCare Center for Genetics and Genomics, of Boston, elected Christine Seidman to the National Academy of Sciences.
The Nantoech Co., of San Diego, appointed Pulickel Ajayan to its scientific advisory board.
Valentis Inc., of Burlingame, Calif., promoted John Reddington chief operating officer.
VaxGen Inc., of Brisbane, Calif., appointed Kevin Lee acting chief financial officer.
Vernalis plc, of London, appointed Sylvia McBrinn senior vice president to head U.S. commercial activities.
ViaGen, of Austin, Texas, said Mark Walton will take the helm of the company.
Vion Pharmaceuticals Inc., of New Haven, Conn., appointed George Bickerstaff and Garry Willis to its board.
Viral Genetics Inc., of Azusa, Calif., appointed Arthur Ammann to its board, and Louis Sullivan to its scientific and medical advisory board.
Vitae Pharmaceuticals, of Fort Washington, Pa., appointed Martin Freed chief medical officer.
Viventia Biotech Inc., of Toronto, appointed nine members to its new head and neck cancer clinical advisory board. They are Richard Schilsky, Gary Clayman, Arlene Forastiere, Patrick Gullane, Merrill Kies, Bert O'Malley, Lillian Siu, Everett Vokes and Barry Wenig.
Voyager Pharmaceutical Corp., of Raleigh, N.C., appointed Jim Artman and William McConville to its board.
Xceleron Ltd., of Heslington, UK, appointed Leslie Chaney U.S. business development director, and Colin Proudfoot finance director.
Xoma Ltd., of Berkeley, Calif., appointed David Boyle chief financial officer.
Zoomedia, of San Francisco, appointed Steven Burrill to its board.
ZymoGenetics Inc., of Seattle, promoted Neil McDonnell to vice president, program management.